Abstract:The RAS–RAF–MEK–ERK pathway is the most well-studied of the MAPK cascades and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation resulting from mutations in components of this pathway, particularly in upstream proteins, RAS and RAF, are responsible for a significant fraction of human cancers and nearly all cutaneous melanomas. Activation of receptor tyrosine kinases by growth factors and various extracellular signals leads to the sequential activation of RAS, RAF, MEK, and finally ERK, which activates numerous transcription factors and facilitates oncogenesis in the case of aberrant pathway activation. While extensive studies have worked to elucidate the activation mechanisms and structural components of upstream MAPK components, comparatively less attention has been directed toward the kinases, MEK and ERK, due to the infrequency of oncogenic-activating mutations in these kinases. However, acquired drug resistance has become a major issue in the treatment of RAS- and RAF-mutated cancers. Targeting the terminal kinases in the MAPK cascade has shown promise for overcoming many of these resistance mechanisms and improving treatment options for patients with MAPK-aberrant cancers. Here, we will describe the role of MEK and ERK in MAPK signaling and summarize the current understanding of their interaction and activation mechanisms. We will also discuss existing approaches for targeting MEK and ERK, and the benefits of alternative strategies. Areas requiring further exploration will be highlighted to guide future research endeavors and aid in the development of alternative therapeutic strategies to combat surmounting drug resistance in treating MAPK-mediated cancers. Visual Overview: http://mcr.aacrjournals.org/content/molcanres/19/3/361/F1.large.jpg .

Role of the Atypical MAPK ERK3 in Cancer Growth and Progression

ERK 3 Signals Through SRC-3 Coactivator to Promote Human Lung Cancer Cell Invasion

Atypical MAPKs in cancer

ERK/MAPK signalling pathway and tumorigenesis

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice

The Activation of ERK3 Signaling Pathway Blocks Cell Proliferation

Molecular insights into the role of mixed lineage kinase 3 in cancer hallmarks

The MAPK Signalling Pathways and Colorectal Cancer

The oncogenic role of protein kinase D3 in cancer

ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Regulation of ERK Signaling Pathway in Biological Behaviors of Tumor Cells

Progress on the research of protein kinase MEKK3

The MEK/ERK Network as a Therapeutic Target in Human Cancer

The function of human epidermal growth factor receptor-3 and its role in tumors (Review).

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers